Chapter 09 Risk Factors

Reproductive and Hormonal Factors

Hormonally related cancers are among the most common cancers worldwide.

Reproductive and hormonal factors, both endogenous (naturally synthesized in the body) and exogenous (man-made), play important roles in the development of common cancers, including breast, endometrial, ovarian, and cervical cancer, with the strength and direction of these associations varying by cancer types (Figure 9.1). Increased access to higher education, evolving social norms, and better availability of and access to contraception have markedly changed women’s reproductive patterns globally and, subsequently, the incidence rates of related cancer types.

Figure 9.1

Reproductive and hormonal factors and cancer risk

Increases risk
Decreases risk
Age Menarche
Older vs younger
Hormonal concraceptive use Fertility drug use Age at first birth
Older vs younger
Having children
Before age 20 years
Having children
After age 20 years
Breast feeding
Long duration vs none
Age Menopause
Older vs younger
Menopause Symptom Hormone
Estrogen only
Menopause Symptom Hormone
Estrogen & Progesterone
Breast
Cervix uteri
Corpus uteri
Ovary

Women are having fewer children (Figure 9.2) and delaying motherhood to older ages (Figure 9.3). The average age of menarche (first menstrual period) has been decreasing, while the average age of menopause (end of menstrual periods) has been increasing. Early menarche, late natural menopause, not having children, and first pregnancy after age 30 increase lifetime exposure to endogenous hormones, thereby increasing the incidence of breast and other hormone-related cancers (see Breast Cancer).

Worldwide, changes in reproductive patterns, such as having fewer or no children and delaying childbirth, influence cancer risk among women.

Figure 9.2

Trends in total fertility rate (number of children per woman) in selected countries, 1950-2023

Footnote

The fertility rate, expressed as the number of children per woman, is based on age-specific fertility rates in a given year.

Figure 9.3

Trends in the mean age of women at birth of first child in selected countries, 1960–2020

Although the protective effect of breastfeeding against breast cancer is well-documented, the current prevalence of breastfeeding in many high-income regions such as North America is lower than the World Health Organization target of 50% in 2023 (Figure 9.4).

Figure 9.4

Percent (%) of infants (aged 0-5 months) exclusively breastfed by UNICEF region, 2022

Footnote

Exclusive breastfeeding means the infant receives only breast milk. No other liquids or solids are given – not even water – with the exception of oral rehydration solution, or drops/syrups of vitamins, minerals or medicines.

Sustained use of exogenous hormones for contraception, reproductive assistance, or menopausal symptoms is associated with a transient increase in breast cancer risk, but a long-term reduction in ovarian and endometrial cancer risk (Figure 9.1). For example, estrogen and progestin combination therapy increases the risk of breast cancer, while it decreases the risk of endometrial cancer.

A new area of research is understanding how exogenous hormone use among individuals undergoing gender-affirming hormonal therapy affects their subsequent cancer risk. There is some evidence emerging that there is an increased risk of breast cancer (but a lower risk of prostate cancer) among transgender women compared to cisgender men, and a lower risk of breast cancer among transgender men compared to cisgender women.

Sources

Text

  • Jackson SS, Hammer A. Cancer risk among transgender adults: A growing population with unmet needs. Acta Obstet Gynecol Scand. Nov 2023;102(11):1428-1430. doi:10.1111/aogs.14686
  • de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. Bmj. May 14 2019;365:l1652. doi:10.1136/bmj.l1652
  • de Nie I, de Blok CJM, van der Sluis TM, et al. Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment. J Clin Endocrinol Metab. Sep 1 2020;105(9):e3293-9. doi:10.1210/clinem/dgaa412
  • Raths F, Karimzadeh M, Ing N, et al. The molecular consequences of androgen activity in the human breast. Cell Genom. Mar 8 2023;3(3):100272. doi:10.1016/j.xgen.2023.100272
  • American Association for Cancer Research. Reducing the Risk of Cancer Development. https://cancerprogressreport.aacr.org/progress/cpr23-contents/cpr23-reducing-the-risk-of-cancer-development/. Accessed August 28, 2024.

Figures